Menu
Submit Data
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Back to Clinical Trials

Ovagen

Glu-Asp-Leu, Liver Bioregulator Peptide

Quick Stats
Studies 34
Trials 30
Overview Studies Clinical Trials
Completed NA INTERVENTIONAL NCT04389918

Tolerability/Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

This study will find out if a meal replacement of this type is satisfying and tolerable for men with prostate cancer. Participants will receive meal replacements of TalityTM as their expected sole source of nutrition for 4 weeks. The purpose of the study is to test whether TalityTM Synthetic Meal Replacements are suitable to be used in larger studies of patients with prostate or other types of cancer.

Detailed Description

Primary Objective: Determine the appeal/tolerability/palatability of a diet consisting solely of TalityTM synthetic meal replacement in participants with prostate cancer Secondary Objective: Evaluate the effect of TalityTM on safety parameters including laboratory tests, nutritional status and adverse effects

Interventions

Name: Tality
Type: OTHER
Description: Synthetic meal replacements, delivered in many varieties of 400 kCal packets, Manufacturer: Filtricine, Inc.

Primary Outcomes

Measure: Proportion of Completers
TimeFrame: 4 weeks
Description: The proportion of participants who complete the 4 week study using TalityTM as their sole source of nutrition at a high level of adherence (75% of days, 21+ days out of the 28 day study).

Trial Information

NCT ID

NCT04389918

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

Stanford University

Last Updated

December 15, 2025

Related Peptides

KPV Thymogen Ovagen Cortagen Livagen Bronchogen Pancragen